Transcription of OPTIDEX T - JP OPHTHALMICS Jamjoom Pharma
1 Aegyptius, Moraxella lacunata, and acinetobacter cal-coaceticus and some Neisseria for injection into the ophthalmic product contains Benzalkonium Chloride as a preservative, which may be deposited in soft contact lenses, therefore this product should not be used while wearing these lenses. These lenses should be removed before application of this product and not re-inserted earlier than 15 minutes after Hypersensitivity to any of the Epithelial herpes simplex keratitis (dendritic kera-titis)
2 , Vaccinia, varicella, and many other viral dis-ease of the cornea and Mycobacterial infections of the Fungal infections of the eye- Following uncomplicated removal of a corneal for-eign GlaucomaSIDE EFFECTSP rolonged topical use of corticosteroids may bring about glaucoma, affecting the optic nerve, causing alterations in the vision. If OPTIDEX -T is administered for more than ten days, ocular pressure should be regularly monitored by the use of corticosteroids may increased risk of secondary ocular infections, masking of an acute infection.
3 As with other antibiotics, prolonged use may bring about the growth of resistant organisms. Treatment should not be withdrawn too early, in order to avoid a renewed outbreak of the wound healing, posterior subcapsular cata-ract IN CHILDRENThe safety and effectiveness of this preparation for children has not been + dexamethasoneSterile Ophthalmic SuspensionDESCRIPTIONEach ml of OPTIDEX - T Suspension contains:Active: Tobramycin 3 mg ( w/v) and Dexamethasone 1 mg ( w/v).
4 Preservative: Benzalkonium Chloride mg ( w/v)PROPERTIESD examethasone is a corticosteroid with anti-inflam-matory properties. It is about 25 times more potent than hydrocortisone in its anti-inflammatory action. Tobramycin is an aminoglycoside antibiotic, which is active against many strains of gram-negative bacte-ria including Pseudomonas the treatment of steroid responsive conditions of the eye when prophylactic antibiotic treatment is also required, after excluding the presence of fungal and viral in suspension is indicated for inflammatory conditions of the palpebral and bul-bar conjunctiva, cornea and anterior segment of the globe.
5 Also indicated in chronic anterior uve-itis, corneal injury from chemical, radiation or ther-mal burns, or from penetration of foreign bodies. Postoperative management of contract, glaucoma and is active against the following com-mon bacterial eye pathogens: Staphylococci, includ-ing S. aureus and S. epidermidis (coagulase-pos-itive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the group of beta-heamolytic species, some non hemolytic species, and some Streptococci, pneu-moniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Heamophilus influenzae and H.
6 OPTIDEX T - JP OPHTHALMICS Jamjoom PharmaUSE IN PREGNANT AND NURSING WOMENIt is not known whether it can cause fetal harm when administered to a pregnant woman. It is not known whether the components of this preparation are excreted in human milk; because many drugs are excreted in human milk, use with caution in nursing C: should be given only if the potential benefit justifies the potential risk to the AND ADMINISTRATIONSI nstill one to two drops of the suspension into the conjunctival sac every four to six hours.
7 During the initial 24 to 48 hours the frequency may be increased to one or two drops every two hours. Do not discontinue treatment at 15 - 25 C. Should not be used more than one month after opening of the Sterile Ophthalmic Suspension, 5 ml in LDPE well before use.
